TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29511785

Group type: EXPERIMENTAL
Intervention: Visuomotor skill training (VT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unilateral slow-paced strength training (SPST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-paced strength training (NPST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 26905901

Group type: EXPERIMENTAL
Intervention: Naltrexone plus prolonged exposure (PE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with no PE
Number of subjects: 0

Group type: COMPARATOR
Intervention: PE plus placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naltrexone without PE
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PTSD severity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in PTSD symptoms and percentage of days drinking
Number of subjects: 0
Study: 23868419

Group type: EXPERIMENTAL
Intervention: HIV care and treatment services
Number of subjects: 3538
Study: 21948457

Group type: EXPERIMENTAL
Intervention: Hydrophilic matrix based modified release formulations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictions of in vivo drug release
Number of subjects: 0
Study: 20881001

Group type: EXPERIMENTAL
Intervention: MVA-5T4
Number of subjects: 733

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733
Study: 18538636

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of the subthalamic nucleus (STN)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Best medical treatment
Number of subjects: 156
Study: 15918525

Group type: EXPERIMENTAL
Intervention: Myung In haloperidol (test drug)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Peridol (reference drug)
Number of subjects: 24
Study: 12893330

Group type: EXPERIMENTAL
Intervention: 200 U of botulinum toxin A
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 30
Study: 10367550

Group type: EXPERIMENTAL
Intervention: Naltrexone tablet (50 mg) plus placebo skin patch
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo tablet plus nicotine skin patch (21 mg/24 h)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Naltrexone tablet plus nicotine skin patch
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo tablet plus placebo skin patch
Number of subjects: 19
Study: 8896495

Group type: EXPERIMENTAL
Intervention: HIV vaccine trial participation willingness
Number of subjects: 1975

Group type: EXPERIMENTAL
Intervention: HIV seroincidence
Number of subjects: 1975

Group type: EXPERIMENTAL
Intervention: HIV seroincidence in subgroup willing to participate
Number of subjects: 1975

Group type: EXPERIMENTAL
Intervention: Independent predictors of HIV seroconversion
Number of subjects: 1975
Study: 1854025

Group type: EXPERIMENTAL
Intervention: 0.4 microgram/kg of dexmedetomidine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 0.2 microgram/kg of dexmedetomidine
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 60 micrograms/kg of oxycodone
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 250 micrograms/kg of diclofenac
Number of subjects: 96
Study: 6340820

Group type: EXPERIMENTAL
Intervention: Levamisole 150 mg for three days, two weekly
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 30608390

Group type: EXPERIMENTAL
Intervention: Verum TENS
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 46
Study: 29082505

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 310
Study: 27296705

Group type: EXPERIMENTAL
Intervention: Atorvastatin/ezetimibe combination
Number of subjects: 246

Group type: COMPARATOR
Intervention: Atorvastatin alone
Number of subjects: 246
Study: 24810181

Group type: EXPERIMENTAL
Intervention: Linifanib administered with food
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Linifanib administered in the evening after a 2-h fast
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Adverse events monitoring
Number of subjects: 34
Study: 22900497

Group type: EXPERIMENTAL
Intervention: U Clip anastomosis
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional anastomosis with 6/0 Prolene
Number of subjects: 31
Study: 19910613

Group type: EXPERIMENTAL
Intervention: Salmeterol with fluticasone propionate
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Salmeterol alone
Number of subjects: 544
Study: 17557214

Group type: EXPERIMENTAL
Intervention: Recommendations for management of varicella zoster virus infections
Number of subjects: 0
Study: 15907955

Group type: EXPERIMENTAL
Intervention: 2.0 g/kg of 100 proof (50% absolute ethanol) vodka
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 12878949

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning with 5 minutes of ischemia and 5 minutes of reoxygenation before 90 minutes of ischemia and 120 minutes of reoxygenation
Number of subjects: 128

Group type: COMPARATOR
Intervention: Simulated ischemia for 90 minutes followed by 120 minutes of reoxygenation
Number of subjects: 128

Group type: COMPARATOR
Intervention: 210 minutes of aerobic incubation (time‐matched control)
Number of subjects: 128
Study: 10654204

Group type: EXPERIMENTAL
Intervention: Salbutamol (S), 100 micrograms/puff, delivered with a metered-dose inhaler (MDI) and a spacer at a tidal volume (VT) of 8 ml/kg (normal VT)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Salbutamol (S), 100 micrograms/puff, delivered with a metered-dose inhaler (MDI) and a spacer at a tidal volume (VT) of 12 ml/kg (high VT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Salbutamol (S) at both tidal volumes (normal and high VT)
Number of subjects: 9
Study: 8543398

Group type: EXPERIMENTAL
Intervention: Epirubicin treatment
Number of subjects: 0
Study: 1858733

Group type: EXPERIMENTAL
Intervention: Formula with molar ratio of 0.9
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Formula with molar ratio of 1.2
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Formula with molar ratio of 1.4
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Formula-fed neonates
Number of subjects: 69

Group type: COMPARATOR
Intervention: Human milk-fed neonates
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Formula-fed groups
Number of subjects: 69
Study: 6351891

Group type: EXPERIMENTAL
Intervention: 10 mg/kg/day of slow release theophylline
Number of subjects: 18
Study: 29178024

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 28409851

Group type: EXPERIMENTAL
Intervention: Combination of oxygen and eszopiclone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo/Air control
Number of subjects: 20
Study: 25755036

Group type: EXPERIMENTAL
Intervention: Screening for diabetes
Number of subjects: 18875

Group type: COMPARATOR
Intervention: No screening (control)
Number of subjects: 18875
Study: 23645340

Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg) 1 hour before surgery and ramosetron immediately after surgery (Dexa‐Ra group, n = 135)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Ramosetron alone (Ra group, n = 134)
Number of subjects: 269
Study: 20948489

Group type: EXPERIMENTAL
Intervention: Elastic compression bandage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inelastic compression bandage
Number of subjects: 0
Study: 18777429

Group type: EXPERIMENTAL
Intervention: Extensive intervention group (2-hour workshops + 2-hour practice session)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Basic intervention group (2-hour workshops)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 57
Study: 17909372

Group type: EXPERIMENTAL
Intervention: Statin users (basic cohort)
Number of subjects: 122406

Group type: EXPERIMENTAL
Intervention: Statin users (after applying 5 restrictions)
Number of subjects: 122406

Group type: EXPERIMENTAL
Intervention: Statin users (multivariable Cox regression after 5 restrictions)
Number of subjects: 122406

Group type: EXPERIMENTAL
Intervention: Statin users (final estimate)
Number of subjects: 122406
Study: 12707578

Group type: EXPERIMENTAL
Intervention: Biologic therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Studies of biologic agents
Number of subjects: 0
Study: 10969369

Group type: EXPERIMENTAL
Intervention: ILM with 0 N elevation force
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ILM with 20 N and 40 N elevation force
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ILM
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ILM at 0 N elevation force
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ILM at 40 N elevation force
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (10 cadavers without ILM)
Number of subjects: 40
Study: 8698440

Group type: EXPERIMENTAL
Intervention: cilazapril (5 mg twice daily)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: sodium nitroprusside
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: acetylcholine
Number of subjects: 22
Study: 1729573

Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Not living alone
Number of subjects: 1234
Study: 6089862

Group type: EXPERIMENTAL
Intervention: Guar gum (22.5 g/l)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Guar gum (36 g/l)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no guar gum)
Number of subjects: 20
Study: 31707982

Group type: EXPERIMENTAL
Intervention: Active comparator arms in head-to-head early RA trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-controlled trials in established RA
Number of subjects: 0
Study: 29411495

Group type: EXPERIMENTAL
Intervention: Telephone-based health coaching (OHH, n = 722)
Number of subjects: 1522

Group type: COMPARATOR
Intervention: Standard care (Control, n = 800)
Number of subjects: 1522
Study: 26822582

Group type: EXPERIMENTAL
Intervention: BFR resistance training
Number of subjects: 40
Study: 24108148

Group type: EXPERIMENTAL
Intervention: quetiapine XR 150 mg/day + SSRI
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: quetiapine XR 300 mg/day + SSRI
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: quetiapine XR 150 mg/day + SNRI
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: quetiapine XR 300 mg/day + SNRI
Number of subjects: 189

Group type: COMPARATOR
Intervention: placebo + SSRI
Number of subjects: 189

Group type: COMPARATOR
Intervention: placebo + SNRI
Number of subjects: 189
Study: 22301929

Group type: EXPERIMENTAL
Intervention: Diet Beverages (DBs)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 318

Group type: COMPARATOR
Intervention: Attention Controls (ACs)
Number of subjects: 318
Study: 19556946

Group type: EXPERIMENTAL
Intervention: Olanzapine plus ECT
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Risperidone plus ECT
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sulpiride plus ECT
Number of subjects: 70
Study: 17457088

Group type: EXPERIMENTAL
Intervention: zidovudine/lamivudine
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: zidovudine/abacavir
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: lamivudine/abacavir
Number of subjects: 128
Study: 15047789

Group type: EXPERIMENTAL
Intervention: Experience Corps Baltimore program
Number of subjects: 0
Study: 12613676

Group type: EXPERIMENTAL
Intervention: Experimental condition (responding to both targets)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (responding to just the second target)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed modality condition (randomly mixed target modality)
Number of subjects: 0
Study: 9569128

Group type: EXPERIMENTAL
Intervention: Cuprophan (CUP)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cellulose diacetate (CDA)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (PMMA)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Polyacrylonitrile (PAN)
Number of subjects: 6
Study: 7856453

Group type: EXPERIMENTAL
Intervention: Cervical electrostimulation (30 minutes, twice a week for a total of 10 sessions, 18 msec duration, 100 Hz frequency)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control groups (same pathology and number of subjects)
Number of subjects: 103
Study: 2510261

Group type: EXPERIMENTAL
Intervention: Rioprostil 600 micrograms/daily
Number of subjects: 243

Group type: COMPARATOR
Intervention: Ranitidine 300 mg/daily
Number of subjects: 243
Study: 182003

Group type: EXPERIMENTAL
Intervention: Meglumine iodoxamate (Cholovue)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Meglumine iodipamide (Cholografin)
Number of subjects: 90
Study: 29482414

Group type: EXPERIMENTAL
Intervention: Individualized physical rehabilitation program (aqua aerobics, conditional swimming, recreational aerobics)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group program (conditional swimming and Pilates exercises)
Number of subjects: 50
Study: 28720715

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 37
Study: 26080882

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 96

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 96
Study: 22708717

Group type: EXPERIMENTAL
Intervention: Adaptive dual n-back program (working memory training group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adaptive visual search program (active placebo-control group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-contact control group (received no practice)
Number of subjects: 0
Study: 21234555

Group type: EXPERIMENTAL
Intervention: Desmopressin (40 mg, nasal spray)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Diclofenac (75 mg, intramuscularly)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Both desmopressin and diclofenac
Number of subjects: 72
Study: 19832818

Group type: EXPERIMENTAL
Intervention: Lornoxicam (LNX) 8‐24 mg/day
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Diclofenac 100‐150 mg/day
Number of subjects: 171
Study: 17875458

Group type: EXPERIMENTAL
Intervention: Strong African American Families (SAAF) program
Number of subjects: 284

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 284
Study: 15746053

Group type: EXPERIMENTAL
Intervention: Oral irinotecan at 80 mg/m(2)/day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oral irinotecan at 70 mg/m(2)/day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oral irinotecan (both dosages)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Food effect on oral irinotecan
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Oral irinotecan
Number of subjects: 25

Group type: COMPARATOR
Intervention: UGT1A1*28 genotype
Number of subjects: 25
Study: 11212049

Group type: EXPERIMENTAL
Intervention: Lateral recumbent head-down position
Number of subjects: 900

Group type: COMPARATOR
Intervention: Lateral recumbent horizontal position
Number of subjects: 900

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 900
Study: 9678288

Group type: EXPERIMENTAL
Intervention: Irbesartan (1 to 900 mg orally)
Number of subjects: 2606

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2606

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 2606
Study: 7986392

Group type: EXPERIMENTAL
Intervention: Thrice weekly injections of GH (group 1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Daily injections of GH (group 2)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo injections (group 3)
Number of subjects: 28
Study: 2692332

Group type: EXPERIMENTAL
Intervention: sodium nitroprusside (SNP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: urapidil
Number of subjects: 20
Study: 31644499

Group type: EXPERIMENTAL
Intervention: Home-based couple intervention
Number of subjects: 487

Group type: COMPARATOR
Intervention: Control (invitation letter for clinic-based couple HIV testing)
Number of subjects: 487
Study: 28446804

Group type: EXPERIMENTAL
Intervention: Increased dose of amlodipine (10 mg) with irbesartan (100 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Indapamide (1 mg) with irbesartan (100 mg) and amlodipine (5 mg)
Number of subjects: 125
Study: 25204992

Group type: EXPERIMENTAL
Intervention: American cranberry (120 mg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Routine prophylactic therapy (control group)
Number of subjects: 62
Study: 23867808

Group type: EXPERIMENTAL
Intervention: QVA149 (110 μg indacaterol/50 μg glycopyrronium)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: QVA149
Number of subjects: 339
Study: 22192313

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training with static/dynamic exercises on a vibratory platform (Frequency: 30‐35 Hz; Amplitude: 2‐4 mm) for 6 weeks (3 sessions/week)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Standard exercise protocol without vibration stimuli for 6 weeks (3 sessions/week)
Number of subjects: 160
Study: 18821005

Group type: EXPERIMENTAL
Intervention: Adaptive Behavior Assessment System‐2nd edition (ABAS‐II)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scales of Independent Behavior‐Revised (SIB‐R)
Number of subjects: 0
Study: 16865033

Group type: EXPERIMENTAL
Intervention: Child-parent psychotherapy (CPP)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Case management plus community referral for individual treatment
Number of subjects: 75
Study: 12872354

Group type: COMPARATOR
Intervention: Cisplatin plus gemcitabine at a 30-minute standard infusion (Arm A)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine at a fixed infusion rate of 10 mg/m2 per minute (Arm B)
Number of subjects: 112
Study: 12027348

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 11475728

Group type: EXPERIMENTAL
Intervention: Integrated Methotrexate (MTX) and Ectopic Pregnancy 2 (EP2) decoction
Number of subjects: 78

Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 78
Study: 7539185

Group type: EXPERIMENTAL
Intervention: Phytotherapeutic agents
Number of subjects: 0
Study: 2693073

Group type: EXPERIMENTAL
Intervention: Clonidine (0.225 mg/day for the first week, increased to 0.450 mg/day for the second week)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 359562

Group type: EXPERIMENTAL
Intervention: Low-dose heparin combined with sulfinpyrazone
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 103
Study: 30954969

Group type: EXPERIMENTAL
Intervention: Gradual tapering of csDMARDs
Number of subjects: 189

Group type: COMPARATOR
Intervention: Gradual tapering of TNF inhibitors
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Gradual tapering of csDMARDs and TNF inhibitors
Number of subjects: 189
Study: 28084083

Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass
Number of subjects: 50

Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass
Number of subjects: 50
Study: 27141690

Group type: EXPERIMENTAL
Intervention: EA‐STEMI
Number of subjects: 196

Group type: COMPARATOR
Intervention: AS‐STEMI
Number of subjects: 196
Study: 23044410

Group type: EXPERIMENTAL
Intervention: Gait training session with ankle mass on non-paretic limb
Number of subjects: 60

Group type: COMPARATOR
Intervention: Gait training session without ankle mass on non-paretic limb
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overground gait training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Treadmill gait training
Number of subjects: 60
Study: 21604206

Group type: EXPERIMENTAL
Intervention: Alcohol-based skin antiseptics (5 different solutions)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reference alcohol 70% propan-2-ol
Number of subjects: 30
Study: 20079220

Group type: EXPERIMENTAL
Intervention: New lesions (Group A)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Late thrombosis (Group B)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Average time from previous PCI to AMI
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 192
Study: 16780618

Group type: EXPERIMENTAL
Intervention: Patient-controlled incisional regional analgesia (PCRA) with ropivacaine 0.25% and 0.5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral analgesics (paracetamol 1 g four times a day and ibuprofen 500 mg three times a day)
Number of subjects: 60
Study: 14982911

Group type: EXPERIMENTAL
Intervention: Self-measured DBP at home (average of 6 measurements per day during 1 week; n = 203)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Average of 3 sitting DBP readings at the physician's office (n = 197)
Number of subjects: 400
Study: 11169172

Group type: EXPERIMENTAL
Intervention: 24% NaCl solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 10
Study: 9007921

Group type: EXPERIMENTAL
Intervention: Anesthetic (2% lidocaine with 1:100,000 epinephrine)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 35
Study: 8285181

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fosinopril (in subset with hypertension)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fosinopril (in subset with type II diabetes and overt proteinuria)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fosinopril (in blacks)
Number of subjects: 26
Study: 31482765

Group type: EXPERIMENTAL
Intervention: Antithyroid drug (ATD) therapy
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Radioactive iodine (131I) therapy
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Second course of ATD
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Ablative treatment (surgery or 131I)
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Levothyroxine replacement
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Normal thyroid hormone status without thyroxine supplementation
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Patients feeling fully recovered
Number of subjects: 1186
Study: 30249609

Group type: EXPERIMENTAL
Intervention: Usual GP care
Number of subjects: 235